Regarded by some as the clearance experts, DCR’s two clinical pharmacology centers offer a broad range of experience within the clinical pharmacology space
Ready access to DaVita® owned hemodialysis and peritoneal dialysis centers
Allows for simplified 24-hour monitoring when conducting dialysis studies
Provides condensed project feasibility by allowing access to our proprietary database system across multiple disease states
Highly specialized trials with focused subject population requiring specific conditions
Conducted more than 90 such trials in the last five years
Enrolled 885 subjects with an average enrollment timeframe of 2-5 months
DCR’s team is headed by Harry Alcorn, Jr., PharmD, Chief Scientific Officer
Conducted over 300 renal protocols
Enrolled over 8,000 subjects with mild, moderate, or severe renal function and those on hemodialysis or peritoneal dialysis
Dr. Alcorn has written over 50 renal protocols and consulted on study design, inclusion/exclusion criteria, and drug-drug interactions in renal patients on over 200 protocols
DCR has the capability to define and understand GFR
A measure of pre-renal blood flow of a drug
Helps understand if there is an impact on renal function and whether it is real or artifact
DCR offers a team of highly experienced and qualified staff
Backed by the DaVita Inc. brand that volunteers and sponsors alike recognize for quality, integrity and safety
An active renal research database for this patient population consists of 567 Pre-ESRD and 2,700 ESRD patients on dialysis